Sun Pharmaceuticals
The Indian pharmaceutical industry is projected to grow at a CAGR of over 10% to reach a size of US$ 130 billion by 2030.
Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets, and capsules. Its businesses include producing generics, branded generics, speciality, over the counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. In FY 2021-22, India branded generics contributed the most to company’s sales with 33% share, followed by US business at 30% share.
- World’s fifth largest specialty generic pharmaceutical company
- Serves over 150 markets across the world
- More than 2,000 marketed products
- More than 40 manufacturing sites
- In FY21, the company’s total income reached US$ 4.5 billion
- Gross sales for Q1 FY22 stood at Rs. 96,694 million (US$ 1.31 billion), up 29% YoY.
Sun Pharma – Reaching People. Touching Lives.
| Year | Milestone |
|---|---|
| 2023 |
Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has launched a novel ophthalmology treatment, CEQUA, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition. Sun Pharma and Israel-based Moebius Medical Limited recently announced the topline results of their Phase 2b, randomized, double-blind, placebo-controlled, singleadministration, multiple-dose study evaluating the efficacy and safety of MM-II for the treatment of knee pain in participants with symptomatic knee osteoarthritis. Sun Pharmaceutical Industries Limited announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc. on March 6, 2023. India's Sun Pharma acquired US-based Concert for US$ 576 million. Sun Pharma Q3 Results: Revenue from operations during the quarter rose 14% to Rs. 11,240 crore (US$ 1.36 billion) against Rs. 9,863 crore (US$ 1.2 billion) in the corresponding quarter of the previous year. Sun Pharma acquired three brands to boost anti-inflammatory portfolio. |
| 2022 |
In November 2022, Sun Pharma and SPARC entered into a license agreement for commercialization of phenobarbital for injection in the US. In May 2022, Sun Pharmaceutical Industries Limited through one of its wholly owned subsidiaries plans to launch Bempedoic Acid under the brand name Brillo, in India for reducing low-density lipoprotein (LDL) cholesterol. In January 2022, Sun Pharma launches PrCEQUA (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL) technology, in Canada. |
| 2021 |
In December 2021, The Drugs Controller General of India (DCGI) has granted Sun Pharma's wholly owned subsidiary Emergency Use Authorization (EUA) to manufacture and distribute Molxvir. In September 2021, with the launch of Revital NXT, Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries Ltd., announced its entry into the nutrition bar category in India. Revital NXT, is a brand extension of Revital H, a health supplement. In June 2021, Sun Pharmaceuticals acquired the patent license for Dapagliflozin from AstraZeneca. The company will distribute and promote the drug under the brand name ‘Oxra’. In May 2021, the company entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company to expand access to the COVID-19 drug, Baricitinib. The company will manufacture and distribute the drug in India. https://www.ndtv.com/business/coronavirus-medicine-covid-19-infection-drug-news-sun-pharma-gains-on-agreement-with-eli-lilly-to-make-baricitinib-in-india-2438740In March 2021, Sun Pharmaceuticals acquired a 12.5% stake in Australia-based WRS Bioproducts for US$ 1.5 million. In February 2021, the company launched a website for its long-term care portfolio in the US, highlighting the efficacy and safety profile for each product. In February 2021, it introduced Brivaracetam, an anti-epileptic drug, in multiple dosage forms, a day after the patent expiry. This drug was developed by UCB, a Belgian-based firm. |
| 2020 |
Sun Pharma announced five-year sustained efficacy and safety results for ILUMYA in patients with moderate-to-severe plaque psoriasis |
| 2019 |
Sun Pharma and AstraZeneca entered into a license agreement for novel oncology products in China |
| 2018 |
Sun Pharma to acquire Pola Pharma in Japan |
| 2018 |
Sales of Rs 27,956 crore (US$ 4 billion) in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for Rs 1502.635 crore (US$ 215 million) |
| 2017 |
Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue |
| 2013 |
Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy |
| 2000 |
Acquired Pradeep Drug Company |
| 1997 |
First international acquisition with Caraco Pharmaceutical Laboratories, USA |
| 1996 |
Sales network expanded across 24 countries |
| 1994 |
Launched initial public offer (IPO) |
| 1989 |
Introduced gastroenterology products in India |
| 1983 |
Established with a portfolio of five psychiatry products |
Partners
